{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".76","upperLimit":"100","value":"0.88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"The progression-free survival time is defined as the time from SCT to progression or death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. Here, we are reporting the proportion of patients that have not had a PFS event one year after SCT.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Sonidegib, Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"All patients that were treated and evaluable were included in this endpoint.","reportingStatus":"POSTED","timeFrame":"Time from SCT to progression or death due to any cause, assessed at 1 year","title":"Progression-free Survival (1 Year Survival Rate)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}